CL2019003789A1 - Tratamiento con plasminógeno de afecciones asociadas a la sobreexpresión de pai-1. - Google Patents

Tratamiento con plasminógeno de afecciones asociadas a la sobreexpresión de pai-1.

Info

Publication number
CL2019003789A1
CL2019003789A1 CL2019003789A CL2019003789A CL2019003789A1 CL 2019003789 A1 CL2019003789 A1 CL 2019003789A1 CL 2019003789 A CL2019003789 A CL 2019003789A CL 2019003789 A CL2019003789 A CL 2019003789A CL 2019003789 A1 CL2019003789 A1 CL 2019003789A1
Authority
CL
Chile
Prior art keywords
pai
overexpression
conditions associated
plasminogen
treatment
Prior art date
Application number
CL2019003789A
Other languages
English (en)
Inventor
Lyne Gagnon
Brigitte Grouix
Pierre Laurin
Original Assignee
Prometic Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prometic Biotherapeutics Inc filed Critical Prometic Biotherapeutics Inc
Publication of CL2019003789A1 publication Critical patent/CL2019003789A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LA INVENCIÓN SE REFIERE AL USO DEL PLASMINÓGENO, UNA VARIANTE DE ESTE, O UN ANÁLOGO QUE TIENE UNA ACTIVIDAD DE PLASMINÓGENO PARA LA PREVENCIÓN O TRATAMIENTO DE UNA AFECCIÓN O UNA ENFERMEDAD QUE SE CARACTERIZA CON UN MAYOR NIVEL DE PAI-1. LAS AFECCIONES Y ENFERMEDADES QUE SE CARACTERIZAN CON UN MAYOR NIVEL DE PAI-1 SE REAGRUPAN DENTRO DE DOS CATEGORÍAS: LAS ENFERMEDADES ASOCIADAS A UNA CAPACIDAD ALTERADA DE REMODELACIÓN TISULAR Y VASCULAR, Y LOS TRASTORNOS METABÓLICOS Y HORMONALES ASOCIADOS A UN MAYOR NIVEL DE PAI-1.
CL2019003789A 2017-06-23 2019-12-20 Tratamiento con plasminógeno de afecciones asociadas a la sobreexpresión de pai-1. CL2019003789A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762523901P 2017-06-23 2017-06-23

Publications (1)

Publication Number Publication Date
CL2019003789A1 true CL2019003789A1 (es) 2020-07-10

Family

ID=64737041

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019003789A CL2019003789A1 (es) 2017-06-23 2019-12-20 Tratamiento con plasminógeno de afecciones asociadas a la sobreexpresión de pai-1.

Country Status (19)

Country Link
US (1) US11826404B2 (es)
EP (1) EP3641888B1 (es)
JP (1) JP2020524689A (es)
KR (1) KR20200019217A (es)
CN (1) CN110831668B (es)
AU (1) AU2018287316B2 (es)
BR (1) BR112019027229A2 (es)
CA (1) CA3068153A1 (es)
CL (1) CL2019003789A1 (es)
DK (1) DK3641888T3 (es)
ES (1) ES2965937T3 (es)
FI (1) FI3641888T3 (es)
IL (1) IL271470A (es)
MX (1) MX2019015741A (es)
RU (1) RU2020100080A (es)
SG (1) SG11201912813SA (es)
TW (1) TW201904990A (es)
WO (1) WO2018234861A1 (es)
ZA (1) ZA202000280B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110114079A (zh) 2016-12-15 2019-08-09 泰伦基国际有限公司 一种预防和治疗肥胖症的方法和药物
TWI750189B (zh) 2016-12-15 2021-12-21 大陸商深圳瑞健生命科學研究院有限公司 一種治療冠狀動脈粥樣硬化及其併發症的方法
CA3047175A1 (en) 2016-12-15 2018-06-21 Talengen International Limited Method for mitigating heart disease
CN115427066A (zh) * 2020-02-06 2022-12-02 泰伦基国际有限公司 一种预防和治疗多发性硬化症的方法和药物
KR20220158036A (ko) * 2020-03-24 2022-11-29 탈렌젠 인터내셔널 리미티드 파킨슨병의 치료 방법 및 약물
CA3176937A1 (en) * 2020-03-24 2021-09-30 Talengen International Limited Method and drug for promoting degradation of misfolded protein and aggregate thereof
KR20220156927A (ko) * 2020-03-24 2022-11-28 탈렌젠 인터내셔널 리미티드 알츠하이머병의 치료 방법 및 약물
CN112174979B (zh) * 2020-10-27 2021-09-07 黑龙江中医药大学 一种治疗多囊卵巢综合征的药物及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5520912A (en) 1993-07-02 1996-05-28 Immuno Aktiengesellschaft Prevention and treatment of ischemic events and reperfusion injury resulting therefrom using lys-plasminogen
US6677473B1 (en) * 1999-11-19 2004-01-13 Corvas International Inc Plasminogen activator inhibitor antagonists
AU3173301A (en) * 2000-02-11 2001-08-20 European Molecular Biology Laboratory Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity
GB0509438D0 (en) 2005-05-09 2005-06-15 Prometic Biosciences Ltd Affinity adsorbets for fibrinogen
CN101573134B (zh) * 2006-08-28 2013-03-06 李季男 抗感染候选药物
US20100028321A1 (en) 2006-08-28 2010-02-04 Omnio Healer Ab Drug target for preventing and treating periodontal disease, improving healing of periodontal wounds and promoting oral health
JP6696899B2 (ja) * 2013-08-13 2020-05-20 サノフイＳａｎｏｆｉ プラスミノーゲン活性化因子阻害剤−１（ｐａｉ−１）に対する抗体及びその使用
TWI801331B (zh) 2015-11-03 2023-05-11 美商波麥堤克生物治療股份有限公司 纖維蛋白溶酶原缺乏症之纖維蛋白溶酶原替代療法
TW201722464A (zh) 2015-11-10 2017-07-01 波麥堤克生化科學有限公司 用於傷口癒合之纖維蛋白溶酶原給藥方案
CN110114079A (zh) * 2016-12-15 2019-08-09 泰伦基国际有限公司 一种预防和治疗肥胖症的方法和药物
EP3556388A4 (en) 2016-12-15 2020-07-08 Talengen International Limited METHOD FOR PREVENTING AND TREATING PATHOLOGICAL KIDNEY DAMAGE
US11154595B2 (en) * 2016-12-15 2021-10-26 Talengen International Limited Method for preventing and treating pulmonary fibrosis

Also Published As

Publication number Publication date
SG11201912813SA (en) 2020-01-30
EP3641888A1 (en) 2020-04-29
AU2018287316A1 (en) 2020-02-06
ZA202000280B (en) 2021-08-25
RU2020100080A3 (es) 2021-11-02
EP3641888A4 (en) 2021-03-10
MX2019015741A (es) 2020-11-11
IL271470A (en) 2020-01-30
TW201904990A (zh) 2019-02-01
AU2018287316B2 (en) 2024-09-19
DK3641888T3 (da) 2024-01-02
RU2020100080A (ru) 2021-07-23
US11826404B2 (en) 2023-11-28
FI3641888T3 (fi) 2023-12-19
KR20200019217A (ko) 2020-02-21
ES2965937T3 (es) 2024-04-17
WO2018234861A1 (en) 2018-12-27
JP2020524689A (ja) 2020-08-20
US20210330761A1 (en) 2021-10-28
CN110831668A (zh) 2020-02-21
BR112019027229A2 (pt) 2020-07-07
CA3068153A1 (en) 2018-12-27
CN110831668B (zh) 2024-04-12
EP3641888B1 (en) 2023-10-11

Similar Documents

Publication Publication Date Title
CL2019003789A1 (es) Tratamiento con plasminógeno de afecciones asociadas a la sobreexpresión de pai-1.
MX2022007989A (es) Composiciones y metodos para tratar pterigion.
EA202090019A1 (ru) Спироциклические индолины в качестве модуляторов il-17
CO2017004715A2 (es) Métodos y formulaciones para tratar enfermedades vasculares de los ojos
BR112018011308A2 (pt) anticorpos de peptídeo de beta amiloide anti-n3pglu e usos dos mesmos
EA201790998A1 (ru) Иммуннорегуляторные агенты
EA201691872A1 (ru) Гетероциклические соединения для применения в лечении pi3k-гамма-опосредованных расстройств
EA201692436A1 (ru) Медицинское применение
BR112016020199A8 (pt) composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso
EA201691320A1 (ru) Способы лечения пациентов с гиперхолестеринемией, которая устойчива к терапии умеренными дозами статинов
AR115583A1 (es) Composiciones y métodos para el tratamiento de las enfermedades y trastornos del hígado
EA201792604A1 (ru) Ингибиторы аутотаксина и их применения
BR112018005114A2 (pt) um novo polipeptídeo de endolisina
EA201892265A1 (ru) Способы лечения офтальмологических заболеваний
MA42657A (fr) Anticorps inhibiteurs anti-pcsk9 destinés au traitement des patients atteints d'hyperlipidémie subissant une aphérèse de lipoprotéines
CR20190471A (es) Moduladores de la expresión de pcsk9
MD3359146T2 (ro) Compoziții farmaceutice și utilizări direcționate spre bolile de depozitare lizozomală
AR111374A1 (es) Uso de lik066 en pacientes con insuficiencia cardíaca
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
EA201991175A1 (ru) Применение в медицине интерферона-лямбда для лечения фиброза
IL283929A (en) Treatment of 22q11.2 deficiency syndrome with cannabidiol
CL2018002128A1 (es) Composiciones y métodos para el tratamiento de heridas crónicas
EA201790893A1 (ru) Способы лечения офтальмологических расстройств
AR116024A1 (es) Métodos de tratamiento de enfermedades neurodegenerativas